Health
Post-Transcriptional Genetic Silencing of BCL11A to Treat Sickle Cell Disease – nejm.org
Original Article from The New England Journal of Medicine — Post-Transcriptional Genetic Silencing of BCL11A to Treat Sickle Cell Disease
From the DanaFarber/Boston Childrens Cancer and Blood Disorders Center, Harvard Medical School (E.B.E., L.E.L., A.B., C.B., M.F.C., B.M., K.B., S.-Y.P., W.B.L., C.D., M.M.H., D.A.W.), the Harvard Stem Cell Institute, Harvard Medical School (A.B., C.B.), the Gene Therapy Program, DanaFarber/Boston Childrens Cancer and Blood Disorders Center (A.B., M.F.C., B.M., E.M., A.F., S.-Y.P., C.D., D.A.W.), the Division of Hematology, Brigham and Womens Hospital, Harvard Medical School (M. Achebe), the Connell…
-
Noosa News12 hours agoTwo teenagers and two adults rushed to hospital in life-threatening conditions after shocking Lawnton house fire
-
Noosa News14 hours agoA secret scheme and plans to expel former leaders — here’s what we’ve heard from Queensland’s inquiry into the CFMEU
-
Noosa News13 hours agoFatal traffic crash, Noosa – Sunshine Coast
-
Business13 hours agoTop brokers name 3 ASX shares to buy next week 23 November 2025